106 related articles for article (PubMed ID: 17310329)
1. Social outcome in adults with maple syrup urine disease (MSUD).
Simon E; Schwarz M; Wendel U
J Inherit Metab Dis; 2007 Apr; 30(2):264. PubMed ID: 17310329
[TBL] [Abstract][Full Text] [Related]
2. Impact of longitudinal plasma leucine levels on the intellectual outcome in patients with classic MSUD.
Hoffmann B; Helbling C; Schadewaldt P; Wendel U
Pediatr Res; 2006 Jan; 59(1):17-20. PubMed ID: 16326996
[TBL] [Abstract][Full Text] [Related]
3. Long-term metabolic follow-up and clinical outcome of 35 patients with maple syrup urine disease.
Abi-Wardé MT; Roda C; Arnoux JB; Servais A; Habarou F; Brassier A; Pontoizeau C; Barbier V; Bayart M; Leboeuf V; Chadefaux-Vekemans B; Dubois S; Assoun M; Belloche C; Alili JM; Husson MC; Lesage F; Dupic L; Theuil B; Ottolenghi C; de Lonlay P
J Inherit Metab Dis; 2017 Nov; 40(6):783-792. PubMed ID: 28905140
[TBL] [Abstract][Full Text] [Related]
4. Variant maple syrup urine disease (MSUD)--the entire spectrum.
Simon E; Flaschker N; Schadewaldt P; Langenbeck U; Wendel U
J Inherit Metab Dis; 2006 Dec; 29(6):716-24. PubMed ID: 17063375
[TBL] [Abstract][Full Text] [Related]
5. Maple syrup urine disease-treatment and outcome in patients of Turkish descent in Germany.
Simon E; Wendel U; Schadewaldt P
Turk J Pediatr; 2005; 47(1):8-13. PubMed ID: 15884622
[TBL] [Abstract][Full Text] [Related]
6. Docosahexaenoic acid status in females of reproductive age with maple syrup urine disease.
Mazer LM; Yi SH; Singh RH
J Inherit Metab Dis; 2010 Apr; 33(2):121-7. PubMed ID: 20217236
[TBL] [Abstract][Full Text] [Related]
7. Young adults with MSUD and their transition to adulthood: psychosocial issues.
Packman W; Mehta I; Rafie S; Mehta J; Naldi M; Mooney KH
J Genet Couns; 2012 Oct; 21(5):692-703. PubMed ID: 22350623
[TBL] [Abstract][Full Text] [Related]
8. Living related versus deceased donor liver transplantation for maple syrup urine disease.
Feier F; Schwartz IV; Benkert AR; Seda Neto J; Miura I; Chapchap P; da Fonseca EA; Vieira S; Zanotelli ML; Pinto e Vairo F; Camelo JS; Margutti AV; Mazariegos GV; Puffenberger EG; Strauss KA
Mol Genet Metab; 2016 Mar; 117(3):336-43. PubMed ID: 26786177
[TBL] [Abstract][Full Text] [Related]
9. A new protein substitute for adolescents and adults with maple syrup urine disease (MSUD).
Hallam P; Lilburn M; Lee PJ
J Inherit Metab Dis; 2005; 28(5):665-72. PubMed ID: 16151896
[TBL] [Abstract][Full Text] [Related]
10. Implications of Maple Syrup Urine Disease in Newborns.
Harris-Haman P; Brown L; Massey S; Ramamoorthy S
Nurs Womens Health; 2017; 21(3):196-206. PubMed ID: 28599741
[TBL] [Abstract][Full Text] [Related]
11. Biochemical correlates of neuropsychiatric illness in maple syrup urine disease.
Muelly ER; Moore GJ; Bunce SC; Mack J; Bigler DC; Morton DH; Strauss KA
J Clin Invest; 2013 Apr; 123(4):1809-20. PubMed ID: 23478409
[TBL] [Abstract][Full Text] [Related]
12. Production and characterization of murine models of classic and intermediate maple syrup urine disease.
Homanics GE; Skvorak K; Ferguson C; Watkins S; Paul HS
BMC Med Genet; 2006 Mar; 7():33. PubMed ID: 16579849
[TBL] [Abstract][Full Text] [Related]
13. Restoration of brain stem auditory-evoked potential in maple syrup urine disease.
Spankovich C; Lustig LR
Otol Neurotol; 2007 Jun; 28(4):566-9. PubMed ID: 17414178
[TBL] [Abstract][Full Text] [Related]
14. Neurocognitive profiles in MSUD school-age patients.
Bouchereau J; Leduc-Leballeur J; Pichard S; Imbard A; Benoist JF; Abi Warde MT; Arnoux JB; Barbier V; Brassier A; Broué P; Cano A; Chabrol B; Damon G; Gay C; Guillain I; Habarou F; Lamireau D; Ottolenghi C; Paermentier L; Sabourdy F; Touati G; Ogier de Baulny H; de Lonlay P; Schiff M
J Inherit Metab Dis; 2017 May; 40(3):377-383. PubMed ID: 28324240
[TBL] [Abstract][Full Text] [Related]
15. Intellectual outcome in children with maple syrup urine disease.
Kaplan P; Mazur A; Field M; Berlin JA; Berry GT; Heidenreich R; Yudkoff M; Segal S
J Pediatr; 1991 Jul; 119(1 Pt 1):46-50. PubMed ID: 2066858
[TBL] [Abstract][Full Text] [Related]
16. Management of maple syrup urine disease in Canada. Committee for improvement of Hereditary Disease Management.
Can Med Assoc J; 1976 Nov; 115(10):1005-13. PubMed ID: 1032577
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of dynamic thiol/disulphide homeostasis as a novel indicator of oxidative stress in maple syrup urine disease patients under treatment.
Zubarioglu T; Kiykim E; Cansever MS; Neselioglu S; Aktuglu-Zeybek C; Erel O
Metab Brain Dis; 2017 Feb; 32(1):179-184. PubMed ID: 27535382
[TBL] [Abstract][Full Text] [Related]
18. [Maple syrup urine disease of neonates: report of two cases and review of literature].
Chen Z; Luo F; Wu XJ; Shi LP
Zhonghua Er Ke Za Zhi; 2010 Sep; 48(9):680-4. PubMed ID: 21092528
[TBL] [Abstract][Full Text] [Related]
19. Glucose and alanine metabolism in children with maple syrup urine disease.
Haymond MW; Ben-Galim E; Strobel KE
J Clin Invest; 1978 Aug; 62(2):398-405. PubMed ID: 670400
[TBL] [Abstract][Full Text] [Related]
20. Case report: Aqueous and Vitreous amino-acid concentrations in a patient with maple syrup urine disease operated on rhegmatogenous retinal detachment.
Kanakis MG; Michelakakis H; Petrou P; Koutsandrea C; Georgalas I
BMC Ophthalmol; 2016 Oct; 16(1):170. PubMed ID: 27716111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
